AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AGENUS INC Director's Dealing 2010

Jan 28, 2010

34023_dirs_2010-01-28_e7cfc1dd-3ac9-456c-b9f8-57581272b041.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANTIGENICS INC /DE/ (agen)
CIK: 0001098972
Period of Report: 2010-01-26

Reporting Person: KLASKIN CHRISTINE M (VP, Finance)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-01-26	Stock Option, right to buy	$0.75	A	75000	Acquired	2020-01-26	Common Stock (75000)	Direct
2010-01-26	Restricted Stock	$	A	30000	Acquired		Common Stock (30000)	Direct

Footnotes

F1: Options granted in accordance with the Antigenics Inc. 2009 Equity Incentive Plan and vest quarterly over three years beginning April 26, 2010.

F2: Restricted stock granted in accordance with the Antigenics Inc. 2009 Equity Incentive Plan and vests quarterly over three years beginning April 26, 2010.